Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Single Arm on the Tolerability of Weekly Nab-paclitaxel

ClinicalTrials.gov ID: NCT01702844

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT01702844. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 8:05 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

LCCC 1210 - Phase II, Multicenter, Single Arm Study of the Tolerability of Weekly Nab-paclitaxel as Second Line Treatment for Elderly Patients With Advanced Lung Cancer

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to evaluate the safety and efficacy of weekly nab-paclitaxel for a second-line treatment in elderly subjects, 70 years of age or greater, with non-small cell lung cancer (NSCLC)

Study identification

NCT ID
NCT01702844
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Enrollment
42 participants

Conditions and interventions

Eligibility (public fields only)

Age range
70 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 25, 2013 (Actual)
Primary completion
Jun 23, 2017 (Actual)
Completion
Jul 12, 2019 (Actual)
Last update posted
Oct 8, 2020

2013 – 2019

United States locations

U.S. sites
8
U.S. states
6
U.S. cities
8
Facility City State ZIP Site status
Highlands Oncology Group Fayetteville Arkansas 72703 —
UNC Lineberger Comprehensive Cancer Center Chapel Hill North Carolina 27599 —
Rex Healthcare Raleigh North Carolina 27607 —
Cleveland Clinic Cleveland Ohio 44195 —
Fox Chase Cancer Center Philadelphia Pennsylvania 19111 —
University of Pittsburgh Medical Center Pittsburgh Pennsylvania 15232 —
Bon Secours Virginia Health System Midlothian Virginia 23114 —
Swedish Cancer Institute Seattle Washington 98104 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01702844, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 8, 2020 · Synced Nov 18, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.